Welcome to Paid Research Studies


Browse Locations ... United States» ... Wyoming» ... Cheyenne





  • Conditions:   Recurrent Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
    Interventions:   Drug: Dabrafenib;   Other: Laboratory Biomarker Analysis;   Drug: Trametinib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified March 2015

  • Conditions:   Adenosquamous Lung Carcinoma;   Large Cell Lung Carcinoma;   Lung Adenocarcinoma;   Stage IB Non-Small Cell Lung Carcinoma;   Stage IIA Non-Small Cell Lung Carcinoma;   Stage IIB Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer
    Interventions:   Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified March 2015

  • Conditions:   Stage IB Non-Small Cell Lung Carcinoma;   Stage IIA Non-Small Cell Lung Carcinoma;   Stage IIB Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer
    Interventions:   Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified March 2015

  • Condition:   Colorectal Cancer
    Interventions:   Biological: cetuximab;   Drug: irinotecan hydrochloride;   Drug: vemurafenib
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Genentech/Roche
    Recruiting - verified July 2015

  • Conditions:   Estrogen Receptor Positive;   HER2/Neu Negative;   Hormone-Resistant Breast Cancer;   Male Breast Carcinoma;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
    Interventions:   Drug: Entinostat;   Drug: Exemestane;   Drug: Goserelin Acetate;   Other: Laboratory Biomarker Analysis;   Other: Placebo;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified April 2015

  • Conditions:   Ovarian Serous Cystadenocarcinoma;   Ovarian Serous Surface Papillary Adenocarcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Letrozole;   Drug: Paclitaxel;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Drug: Tamoxifen Citrate;   Drug: Topotecan Hydrochloride;   Drug: Trametinib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2015

  • Conditions:   Anemia;   Fever, Sweat, and Hot Flashes;   Stage I Chronic Lymphocytic Leukemia;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Small Lymphocytic Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma;   Weight Change
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Biological: Rituximab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2015

  • Conditions:   Estrogen Receptor Positive;   HER2/Neu Positive;   Progesterone Receptor Positive;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
    Interventions:   Drug: Aromatase Inhibition Therapy;   Drug: Carboplatin;   Drug: Docetaxel;   Drug: Goserelin Acetate;   Other: Laboratory Biomarker Analysis;   Biological: Pertuzumab;   Other: Quality-of-Life Assessment;   Procedure: Therapeutic Conventional Surgery;   Biological: Trastuzumab;   Radiation: Whole Breast Irradiation
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified February 2015

  • Conditions:   Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
    Interventions:   Drug: Bendamustine Hydrochloride;   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Biological: Rituximab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified April 2015

  • Conditions:   Breast Cancer;   Musculoskeletal Complications;   Pain
    Interventions:   Drug: duloxetine hydrochloride;   Other: placebo
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified July 2015

  • Conditions:   Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Cervical Squamous Cell Carcinoma;   Chemotherapeutic Agent Toxicity;   Cognitive Side Effects of Cancer Therapy;   Psychological Impact of Cancer;   Radiation Toxicity;   Sexual Dysfunction and Infertility;   Stage IB Cervical Cancer;   Stage IIA Cervical Cancer;   Stage IIB Cervical Cancer;   Stage III Cervical Cancer;   Stage IVA Cervical Cancer
    Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Radiation: External Beam Radiation Therapy;   Radiation: Internal Radiation Therapy;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment
    Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified July 2015

  • Condition:   Colorectal Neoplasms
    Interventions:   Drug: Eflornithine placebo & sulindac placebo;   Drug: eflornithine & sulindac placebo;   Drug: Eflornithine placebo & sulindac;   Drug: Eflornithine plus sulindac
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Cancer Prevention Pharmaceuticals, Inc.
    Recruiting - verified July 2015

  • Conditions:   Ductal Breast Carcinoma In Situ;   Estrogen Receptor and/or Progesterone Receptor Positive;   HER2/Neu Negative;   Invasive Breast Carcinoma;   Multicentric Breast Carcinoma;   Multifocal Breast Carcinoma;   Synchronous Bilateral Breast Carcinoma
    Interventions:   Drug: Anastrozole;   Drug: Exemestane;   Other: Laboratory Biomarker Analysis;   Drug: Letrozole;   Other: Quality-of-Life Assessment;   Drug: Systemic Chemotherapy;   Drug: Tamoxifen Citrate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified March 2015

  • Conditions:   Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Cervical Squamous Cell Carcinoma;   Stage IA Cervical Cancer;   Stage IB Cervical Cancer;   Stage IIA Cervical Cancer
    Interventions:   Drug: Cisplatin;   Radiation: External Beam Radiation Therapy;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
    Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified July 2015

  • Conditions:   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Mucinous Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Malignant Ovarian Brenner Tumor;   Malignant Ovarian Mixed Epithelial Tumor;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Adenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Cancer;   Stage III Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma
    Interventions:   Behavioral: Behavioral Dietary Intervention;   Behavioral: Compliance Monitoring;   Other: Counseling;   Other: Educational Intervention;   Behavioral: Exercise Intervention;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified July 2015

  • Conditions:   Clear Cell Adenocarcinoma;   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Mucinous Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Malignant Ovarian Mixed Epithelial Tumor;   Mucinous Adenocarcinoma;   Ovarian Brenner Tumor;   Ovarian Clear Cell Adenocarcinofibroma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Serous Adenocarcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Carcinoma;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma
    Interventions:   Biological: Bevacizumab;   Drug: Carboplatin;   Drug: Docetaxel;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified July 2015